In contrast, Song et al. claimed that ZEB1 inhibition promotes CHK1 phosphorylation and induces cell cycle arrest in the interphase and thus sensitizes p53-mutated pancreatic cancer cells to the therapy by ATR inhibitor, whereas ZEB1 overexpression attenuates chemotherapy-stimulated CHK1 phosphorylation (Song et al., 2018). Here, ZEB1 is linked to familial pancreatic carcinoma.